Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sodium hematoporphyrin PDT plus gemcitabine/cisplatin for advanced extrahepatic cholangiocarcinoma with biliary obstruction
CTR20254544Phase 2Active
- Sponsor
- Qinglong High-Tech
- Start
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sodium hematoporphyrin, gemcitabine, cisplatin in extrahepatic cholangiocarcinoma (eCCA), sponsored by Qinglong High-Tech. Started Jul 2026; status: active.
02
Drugs
sodium hematoporphyringemcitabinecisplatin
03
Conditions
extrahepatic cholangiocarcinoma (eCCA)
Beyond the preview
Go deeper on CTR20254544.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254544.